linjc16/ctgov huggingface dataset:
Bronchial Dilation Test in Wheezy Infants

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to establish the methodology of bronchial dilation test by salbutamol MDI with Spacer in wheezy infants with asthma and to evaluate the effects of atopy on the exacerbation of wheeze in wheezy infants.

Detailed Description
-----------------
After screening,each participant undergo baseline pulmonary function test(Jaeger Master Screen Baby Body, Germany)and post-bronchodilator measurements that performed 10min after 200ug of salbutamol administered using a metered-dose inhaler and a spacer. The participants undergo baseline lung function test and bronchial dilation tests on the second and third visits with one-month interval,and whenever there is an exacerbation.

Official Title
-----------------
Brochial Dilation Test by Salbutamol Metered Dose Inhaler(MDI) With Spacer in Wheezy Infants With Asthma Risk Factors

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: normal term infants.Recurrent wheezing with or without atopy,none of the subjects had a history of respiratory illness, congenital heart disease,dysphagia,oxygen saturation≤90% on room air,an active seizure disorder,or upper airway obstruction,or requirement for assisted ventilation in the neonatal periods,all infants were asymptomatic for at least 2 weeks preceding the test. Exclusion Criteria: subjects had a history of respiratory illness, congenital heart disease,dysphagia,oxygen saturation≤90% on room air,an active seizure disorder,or upper airway obstruction,;all infants were asymptomatic for at least 2 weeks preceding the test.

Ages Eligible for Study
-----------------
Minimum Age: 5 Months
Maximum Age: 36 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy<br>healthy control, 5 months to 3 years | |
| wheezing with atopy<br>suspected asthma with wheezing (>3 episodes per year) and atopy | |
| wheezing without atopy<br>wheezing without atopy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| airway resistance(Raw) performed by body plethysmography before and after bronchial dilation test. | airway resistance(Raw) at rest | Change from baseline at 20 mins after inhalation of salbutamol | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| airway resistance(Raw) performed by body plethysmography | airway resistance(Raw) measured within 24 hours whenever there is an exacerbation of wheeze. | at 24 hours of the exacerbation of wheeze | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infants, asthma, bronchial dilation test, plethysmography
Efficacy and Safety of Itopride vs Placebo in Heartburn

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of itopride in patients with heartburn.

Official Title
-----------------
A Randomized, Double-blind, Two Period, Crossover Study to Evaluate the Effects of a Single Dose of Itopride 200 mg on Esophageal and Gastric pH and Reflux in Patients With Heartburn

Conditions
-----------------
Heartburn

Intervention / Treatment
-----------------
* Drug: Itopride
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Otherwise healthy males and females aged 18-70, with at least 3 episodes of heartburn or acid regurgitation per week.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Itopride|nan|
|Drug: Placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 24-hour pH Monitoring |  | after 5 days of treatment |
Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19

Study Overview
=================
Brief Summary
-----------------
Fatigue is common and disabling in patients with post-COVID syndrome. There is no treatment available at this moment, and fatigue has important consequences. The main aim of this study is to evaluate the changes in the severity of fatigue using non-invasive neuromodulation in patients with post-COVID condition. This is a randomized, parallel, double-blind, placebo-controlled clinical trial using transcranial direct current stimulation. Secondary aims include changes in cognition, depression, and quality of life.

Official Title
-----------------
Modulation of Post-COVID-19 Fatigue Using Transcranial Direct Current Stimulation. Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Device: Active tDCS
* Device: Sham tDCS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of COVID-19 with PCR-confirmation. Fatigue linked to COVID-19 No diagnosis of neurological, psychiatric or medical disorder with potential impact on fatigue. Exclusion Criteria: Stroke before COVID-19 History of traumatic brain lesion or central nervous system infection previous to COVID-19 Radiotherapy or chemotherapy for cancer Severe sensorial deficits Drugs or uncontrolled medical disorder with potential impact on fatigue. History of abuse of alcohol or other toxics. Any contraindication for tDCS (metallic implants, brain devices, pacemakers, head injuries).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Active tDCS<br>Transcranial current direct stimulation. 8 days. | Device: Active tDCS<br>* Eight sessions of transcranial current direct stimulation<br>|
| Sham Comparator: Sham tDCS<br>Sham transcranial current direct stimulation. 8 days. | Device: Sham tDCS<br>* Eight sessions of transcranial current direct stimulation (sham)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Fatigue | Modified Fatigue Impact Scale (MFIS) | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cognition | Stroop Test | 2 weeks | 
| Change in depressive symptoms | Beck Depression Inventory II | 2 weeks | 
| Change in quality of life | EuroQuol-5D | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post-COVID-19 syndrome, Post-COVID-19 condition, Persistent COVID-19, Long-Haul COVID-19, Fatigue
Monitoring of Non-invasive Ventilation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether clinical examination, report from ventilator software, nocturnal Sp02 and daytime arterial blood gas are sufficient as screening tools to reveal clinical relevant problems with patients receiving long term treatment with non invasive ventilation.

Detailed Description
-----------------
Patient with chronic hypoventilation with stable on long term treatment (LTMV) with non-invasive ventilation for at least 3 month taking part of our LTMV program will be included. In addition to clinical examination,report from ventilator software, nocturnal Sp02 and daytime arterial blood gas all patients will be investigated with sleep polygraphy and transcutaneous Co2.

Official Title
-----------------
Monitoring of Non-invasive Ventilation

Conditions
-----------------
Hypoventilation

Participation Criteria
=================
Eligibility Criteria
-----------------
Admitted to our unit for optimal treatment of long term non invasive ventilation Readmitted for control after 6-8 weeks Then treated for at least 3 month with long term non invasive ventilation outside of hospital. Informed written consent Exclusion Criteria: Under 18 years old Lack of cooperation Pregnant Acute exacerbation last 3 month leading to hospital admission. Change of treatment last 3 month

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non invasive ventilation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of transcutaneous co2 revealing sleep hypoventilation, when nocturnal pulseoximeter is normal |  | single night study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of patient-ventilator asynchrony during non invasive ventilation ? |  | Single night study |
Genetic Analysis of Liver Cancer

Study Overview
=================
Brief Summary
-----------------
Liver cancer is a leading cause of cancer deaths worldwide. While the molecular pathogenesis of liver cancer has been extensively studied, less is known about how the molecular biology of liver cancer influences clinical outcome and treatment response. We are developing a translational research program that will characterize molecular changes in liver cancer. We plan to use molecular information obtained from studying liver tumor tissues to develop new diagnostics and treatment regimens for patients with these cancers. The experimental approach will require freezing fresh tumor tissues obtained from surgical procedures, which will be subsequently used for analysis of DNA, protein and mRNA expression. Many patients with liver cancer are referred to the Stanford Liver Tumor Board for consultation and treatment recommendations. We propose to gather tissue samples from those who subsequently undergo biopsy, liver resection surgery, or transplant surgery.

Official Title
-----------------
Genetic Analysis of Liver Cancer

Conditions
-----------------
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers, Hepatobiliary Cancers Liver

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:3.1.1 Male or female patients 18 years of age and above. 3.1.2 Patients diagnosed with liver cancer based on biopsy or serum alpha-fetoprotein level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. Patients with metastatic tumor from anther organ, such as metastatic colon cancer. 3.13 Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:3.2.1Female patients who are pregnant or nursing will be excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
How Important Are Hematological Parameters in the Prognosis of Severe Covid-19 Patients?

Study Overview
=================
Brief Summary
-----------------
It is aimed to reveal the treatment and prognostic values by evaluating the differences in hematological parameters and indices, especially in dead Covid-19 cases. Material Method: It is planned to retrospectively examine the hemogram parameters of 125 male, 44 female and 169 critical Covid-19 patients hospitalized between 01.03.2020 and 31.12.2021. Subjects were divided into 2 groups as deceased (77) and living (92) patients according to demographic data such as age and gender. Statistical evaluation: All analyzes were SPSS 25.0, Kolmogorov Smirnov test was used to determine distribution, median and interquartile range (Tukey's Hinges Percentile) were used to summarize variables. The differences between the Independent-Samples Mann Whitney U Test and the data of the patient groups and the optimal cut-off values, sensitivity and specificity values will be determined by ROC analysis. It will be considered statistically significant when the p value is below 0.05 (with the two-tailed test)

Detailed Description
-----------------
The aim of this study is to examine the effectiveness of routine laboratory complete blood count parameters and rates as diagnostic and prognostic criteria in severe COVID-19.

Official Title
-----------------
Department of Infectious Disease and Clinical Microbiology

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Diagnostic Test: Hemogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over the age of 18 Critical patients taken to intensive care The length of stay in the ICU is more than 24 hours Exclusion Criteria: 1) Patients under 18 years of age (2) Patients with hematological malignancies (3) The length of stay in the ICU is less than 24 hours.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Covid-19 Survivor groups<br>Covid-19 survivor groups are hematological parameters | Diagnostic Test: Hemogram<br>* Sysmex XN-1000 hematological analyzer<br>|
| Covid-19 Non-survivor groups<br>Hematological parameters in patients with severe COVID-19 who have died. | Diagnostic Test: Hemogram<br>* Sysmex XN-1000 hematological analyzer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hematological parameters in the prognosis of severe Covid-19 patients. | Hemogram values of the deceased and surviving patients participating in the study were compared. | 2020-2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NLR, Hemogram, MPV/PLT, MPV/PCT
Logan Basic Technique Measured by Surface Electromyography (EMG)

Study Overview
=================
Brief Summary
-----------------
The purpose of this investigation is to determine the effect of Logan Basic Technique apex contact adjustment (LBT); on the motor recruitment pattern in the erector spinae group via surface EMG.

Detailed Description
-----------------
LBT is a low force adjusting technique that focuses on the foundation segment of the spine, the sacrum, with application of contact on the sacrotuberous ligament which relieves fatigued and strained muscles, particularly intrinsic muscles of the back. Surface electromyography (EMG) is a method of analyzing the activity level of superficial muscles. It is convenient and advantageous when studying muscle relaxation which occurs in biofeedback studies

Official Title
-----------------
The Effect of Logan Basic Technique Apex Contact Adjustment on the Motor Recruitment Pattern in the Erector Spinae.

Conditions
-----------------
Spinal Manipulation

Intervention / Treatment
-----------------
* Procedure: Logan Basic Technique and Surface EMG
* Other: Surface EMG
* Procedure: Logan Basic Technique Sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Students in trimesters 1 - 3. Naive to the Logan Basic Technique adjusting protocol. Exclusion Criteria: Students in trimesters 4 - 10. Pregnant females or females who can possibly be pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br>Participant will receive a brief exam, a Basic Technique apex contact adjustment and Surface EMG. | Procedure: Logan Basic Technique and Surface EMG<br>* Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.<br>Other: Surface EMG<br>* Surface EMG only, no intervention<br>|
| Sham Comparator: Sham<br>Participants will receive a sham Basic Technique adjustment (an adjacent contact not indicated by examination)and surface EMG. | Other: Surface EMG<br>* Surface EMG only, no intervention<br>Procedure: Logan Basic Technique Sham<br>* Participants will receive a sham Basic Technique treatment, not indicated by examination.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surface EMG |  | 15 minute sEMG: 5 mins before, 5 mins during and 5 mins after intervention |
Analgesic Efficacy of Oral Glucose in Preterm Neonates During Suctioning

Study Overview
=================
Brief Summary
-----------------
Nasopharyngeal suctioning is a painful procedure that often becomes necessary in the care of preterm infants under CPAP therapy several times a day. Since the use of analgetic and sedative drugs is accompanied with multiple side effects these are usually being avoided. Glucose 20% has been shown to have an analgesic effect when administered to preterm infants previous to some painful procedures (i.e blood sampling). In this clinical trial the efficacy of orally administered Glucose 20% for relieving the procedural pain of nasopharyngeal suctioning is tested. The investigators' study has a cross-over design and is to include 40 patients.

Official Title
-----------------
Prospective, Placebo-Controlled Blinded Clinical Trial to Study the Efficacy of Orally Administered Glucose 20% for Relieving Pain During Nasopharyngeal Suctioning in Preterm Infants > 1500g Under CPAP-Therapy

Conditions
-----------------
Analgesia

Intervention / Treatment
-----------------
* Drug: Glucose 20%
* Drug: Aqua


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preterm newborns (>1500g birth weight) up to a gestational age of 36+6 weeks CPAP respiratory therapy Parents' given written consent Exclusion Criteria: Diseases complicating neuromuscular evaluation. Drug abuse by the mother Administration of other analgetic or sedative drugs within the previous 48h. Participation in another interventional clinical trial within 4 weeks before the beginning of this trial.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Glucose 20%<br> | Drug: Glucose 20%<br>* The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning<br>|
| Placebo Comparator: placebo<br> | Drug: Aqua<br>* The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The PIPP-Score, a validated pain-score, is used to measure the patient's pain |  | during nasopharyngeal suctioning | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
analgesia, infant, premature, glucose, nasopharyngeal suctioning
Endoscopic Stenting for Chronic Abdominal Pain

Study Overview
=================
Brief Summary
-----------------
The prospective sham randomized study will evaluate the role of endoscopic stenting inpatients with chronic pancreatitis and chronic abdominal pain.

Detailed Description
-----------------
Endoscopic stenting is increasingly used for the treatment of a variety of pancreatic disorders. Although a number of studies suggest that pancreatic stenting relieves abdominal pain in approximately 70% of patients, there has been no randomized study. Since any intervention may improve pain, the effectiveness of endoscopy cannot be ascertained without a true placebo arm or sham therapy group. The study will aim to determine the effectiveness of pancreatic stents in relieving chronic pain in the setting of chronic pancreatitis. Since these procedures do carry risk, a placebo controlled fashion is used for this study

Official Title
-----------------
Randomized Single Blind Trial of Endoscopic Stenting for Chronic Pancreatitis-Associated Abdominal Pain

Conditions
-----------------
Chronic Pancreatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients referred to the principal investigator for chronic pancreatitis will be enrolled. Exclusion Criteria: There are no gender nor racial exclusion.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |